Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Eisai Co Ltd | 16 |
| 2 | Rohto Pharmaceutical Co Ltd | 12 |
| 3 | Glaukos Corp | 7 |
| 4 | Imperial Brands PLC | 7 |
| 5 | Ajinomoto Co Inc | 6 |
| 6 | Resonac Holdings Corp | 6 |
| 7 | Daiichi Sankyo Co Ltd | 4 |
| 8 | Hisamitsu Pharmaceutical Co Inc | 4 |
| 9 | Arturus Capital Ltd | 3 |
| 10 | Chinese University of Hong Kong | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 54 |
| 2 | A61P | Therapeutic activity (drug indications) | 42 |
| 3 | C07D | Heterocyclic compounds | 24 |
| 4 | A23L | Foods and beverages (general) | 12 |
| 5 | G01N | Investigating / analysing materials | 12 |
| 6 | A23V | Foods, foodstuffs - indexing scheme | 11 |
| 7 | A61N | 8 | |
| 8 | A61Q | Cosmetics, personal care | 8 |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 6 |
| 10 | A24B | 6 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| MEDICINAL COMPOSITION | 2006 | Eisai Co Ltd | 68 |
| NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | 2005 | Eisai Co Ltd | 45 |
| NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | 2005 | Eisai Co Ltd | 42 |
| Tofacitinib citrate pharmaceutical composition | 2017 | 14 | |
| Skin color-improving agent and composition for improving skin color | 2017 | Resonac Holdings Corp | 12 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 51 |
| 2017 | 62 |
| 2018 | 62 |
| 2019 | 65 |
| 2020 | 47 |
| 2021 | 45 |
| 2022 | 52 |
| 2023 | 30 |
| 2024 | 44 |
| 2025 | 15 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gordon Tollin | University of Arizona | 37 |
| 2 | Stephen G. Mayhew | University College Dublin | 35 |
| 3 | Vincent Massey | University of Michigan | 21 |
| 4 | J. Woodland Hastings | Harvard University | 20 |
| 5 | Franz Müller | Graduate School Experimental Plant Sciences | 18 |
| 6 | Nigel S. Scrutton | University of Manchester | 18 |
| 7 | Changjian Feng | University of New Mexico | 17 |
| 8 | David Leys | University of Manchester | 16 |
| 9 | Donald B. McCormick | Cornell University | 16 |
| 10 | Marta Martínez‐Júlvez | Universidad de Zaragoza | 12 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure | 1999 | 3864 | Bacterial Genetics and Biotechnology |
| Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase | 1991 | 2363 | Nitric Oxide and Endothelin Effects |
| Purification and characterization of the flavoenzyme glutathione reductase from rat liver. | 1975 | 2026 | Redox biology and oxidative stress |
| Shewanella secretes flavins that mediate extracellular electron transfer | 2008 | 1988 | Electrochemical sensors and biosensors |
| Generation of reactive oxygen species by the mitochondrial electron transport chain | 2002 | 1244 | Alzheimer's disease research and treatments |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Riboflavin 5'-phosphate sodium?
Which organizations hold the most patents involving this compound?
What is the trend in patent filings for this compound in recent years?
Which author has published the most papers on this compound?
What are the primary patent classification codes associated with this compound?